Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cara Therapeutic

CARA
Current price
5.04 USD +0.05 USD (+1.00%)
Last closed 5.04 USD
ISIN US1407551092
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 14 152 718 USD
Yield for 12 month -27.96 %
1Y
3Y
5Y
10Y
15Y
CARA
21.11.2021 - 28.11.2021

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Address: 400 Atlantic Street, Stamford, CT, United States, 06901

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.01 USD

P/E ratio

Dividend Yield

Current Year

+20 968 000 USD

Last Year

+41 867 000 USD

Current Quarter

+2 556 000 USD

Last Quarter

+991 000 USD

Current Year

+14 794 000 USD

Last Year

+34 601 000 USD

Current Quarter

+2 556 000 USD

Last Quarter

+991 000 USD

Key Figures CARA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -104 724 000 USD
Operating Margin TTM -1 636.13 %
PE Ratio
Return On Assets TTM -63.43 %
PEG Ratio
Return On Equity TTM -184.32 %
Wall Street Target Price 1.01 USD
Revenue TTM 10 996 000 USD
Book Value 1.05 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -85.70 %
Dividend Yield
Gross Profit TTM -56 141 000 USD
Earnings per share -1.75 USD
Diluted Eps TTM -1.75 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CARA

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CARA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:2
Payout Ratio
Last Split Date 16.01.2014
Dividend Date

Stock Valuation CARA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 4.83
Price Sales TTM 1.29
Enterprise Value EBITDA -2.32
Price Book MRQ 20.02

Financials CARA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CARA

For 52 weeks

0.24 USD 1.15 USD
50 Day MA 0.29 USD
Shares Short Prior Month 1 260 295
200 Day MA 0.48 USD
Short Ratio 2.20
Shares Short 576 662
Short Percent 2.00 %